About Kyverna Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://kyvernatx.com/
Frequently Asked Questions
What is the 52-week range for KYTX?
The 52-week high is $13.67 and the 52-week low is $5.3.
What is the P/E ratio for KYTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for KYTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -81.91%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.31.
Analyst Recommendation Trends
Wall Street analyst consensus for KYTX over the last few months:
Latest KYTX News
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
Chief executive Warner Biddle said the therapy’s durability “exceeded even our expectations.”
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow
2026-09-24. The following slide deck was published by Kyverna Therapeutics, Inc.
Kyverna stock jumps on positive one-year therapy data
Investing.com -- Kyverna Therapeutics Inc (NASDAQ:KYTX) shares rose nearly 10% in early trade Thursday following the release of positive one-year durability data for its miv-cel therapy in stiff person syndrome and generalized myasthenia gravis.
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials September 24, 2026 8:00 AM EDTCompany...
Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions
Kyverna Therapeutics reports positive one-year clinical trial data for miv-cel in stiff person syndrome and myasthenia gravis.
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
Kyverna Therapeutics (NASDAQ:KYTX) reported one-year topline data from its KYSA-8 registrational trial of miv-cel, or mivocabtagene autoleucel, in stiff person syndrome (SPS), alongside longer-term follow-up results from the Phase 2 portion of its KYSA-6 trial in generalized myasthenia gravis (gMG). The company said the latest results provide follow-up on clinical outcomes and safety measures after patients received a single dose of the investigational cell therapy.
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission on track for completion in Q4 2026 Longer-term Phase 2 follow-up in gMG demonstrat
Kyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct
Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kyverna Therapeutics, Inc. (KYTX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:05 PM EDTCompany ParticipantsWarner Biddle -...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-27 | Aktar Mert | +20,582 | - | - |
| 2026-05-27 | Aktar Mert | +5,093 | - | - |
| 2026-05-27 | Shaw Christi | -4,194 | $8.59 | $36,026 |
| 2026-05-27 | Cohen Fred E | +20,582 | - | - |
| 2026-05-27 | Cohen Fred E | +5,093 | - | - |
| 2026-05-27 | CLARK IAN T | +20,582 | - | - |
| 2026-05-27 | CLARK IAN T | +5,093 | - | - |
| 2026-05-27 | SEIDENBERG BETH C | +20,582 | - | - |
| 2026-05-27 | SEIDENBERG BETH C | +5,093 | - | - |
| 2026-05-04 | Dac Nadia | +300,000 | - | - |
| 2026-03-13 | GEHCHAN NAJI | +105,000 | - | - |
| 2026-03-13 | GEHCHAN NAJI | +18,000 | - | - |
| 2026-03-13 | Biddle Warner Weston | +350,000 | - | - |
| 2026-03-13 | Biddle Warner Weston | +58,000 | - | - |
| 2026-03-13 | GRASSO MARC | +65,000 | - | - |
| 2026-03-13 | GRASSO MARC | +10,000 | - | - |
| 2026-02-24 | Emany Sravan Kumar | +42,945 | - | - |
| 2026-02-24 | Emany Sravan Kumar | +11,006 | - | - |
| 2026-02-24 | Miller Andrew Craig | +42,945 | - | - |
| 2026-02-24 | Miller Andrew Craig | +11,006 | - | - |
| 2026-02-09 | Pujols Mayobanex | +300,000 | - | - |
| 2026-01-12 | Shaw Christi | +185,000 | - | - |
| 2026-01-12 | Shaw Christi | +24,301 | - | - |
| 2026-01-12 | Shaw Christi | +30,000 | - | - |
| 2025-12-18 | Westlake BioPartners Fund I, L.P. | +133,333 | $7.5 | $999,998 |
| 2025-12-18 | SEIDENBERG BETH C | +133,333 | $7.5 | $999,998 |
| 2025-12-15 | Walker Karen Marie | -23,998 | - | - |
| 2025-12-15 | Walker Karen Marie | -23,998 | $12.2 | $292,776 |
| 2025-12-15 | Walker Karen Marie | +23,998 | $4.83 | $115,910 |